SuperworthAvalo Therapeutics shares outstanding AVTX
Diluted shares outstanding, averaged over each quarter, from 2014.
- Latest quarter, to Jun 30, 2026
- 43.6M
- On a year earlier
- +302.6%
- more shares
Avalo Therapeutics had 43.6M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 302.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 18.2M | +78% |
| FY2024 | 10.2M | +1171% |
| FY2023 | 801.6K | +1942% |
| FY2022 | 39.2K | +177% |
| FY2018 | 14.2K | +42% |
| FY2017 | 10K | +210% |
| FY2016 | 3.2K | +1340% |
| FY2014 | 223 | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 43.6M | +303% | |
| Q1 FY26 | 20.1M | +91% | |
| Q4 FY25 | 18.2M | +78% | |
| Q3 FY25 | 14M | +30% | |
| Q2 FY25 | 10.8M | +42% | |
| Q1 FY25 | 10.5M | +1124% | |
| Q4 FY24 | 10.2M | +1171% | |
| Q3 FY24 | 10.8M | +5435% | |
| Q2 FY24 | 7.7M | +13046% | |
| Q1 FY24 | 859.4K | +1659% | |
| Q4 FY23 | 801.6K | +1942% | |
| Q3 FY23 | 194.9K | +397% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Avalo Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.